## All Inpatient (IP) stays 2) All IP stays in children <18 years with COVID-19 diagnosis 3) All IP stays in children <18 years with Multisystem Inflammatory Syndrome (MIS-C) diagnosis Discharge Admit Date Query start date: Query end date: All IP stays in children <18 years with COVID-19 diagnosis and Intensive Care Unit (ICU) admission date 02/20/2020 (Day 0) 09/30/20211 Length of stay <sup>1</sup>Includes discharges 1) Admission Date: Year/Month for final billed **Baseline characteristics** patients only. The 2) Demographics: Sex; Race; Age; Ethnicity examined on admission analysis does not Geographic distribution: State include inpatient stays for patients 1) Newborn (documented live birth) still admitted or not completely coded. 2) High risk conditions: Asthma; Chronic obstructive pulmonary disease; Cystic fibrosis; Tuberculosis; Other chronic respiratory Conditions examined any disorders; Diabetes; Heart failure; Cardiovascular disease; Congenital heart disease; Sickle cell disease or thalassemia; Mental health <sup>2</sup>Respiratory support time during the stay conditions; Down syndrome; Liver and renal disorders; Obesity; Immunocompromised state; Malignant cancer; Smoking was defined using 4) SARS-CoV-2 test performed standardized nursing documentation 1) Pulmonary complications: Viral pneumonia; Acute respiratory failure; Acute respiratory distress syndrome 2) Other complications: Sepsis; Myocarditis; Pericarditis; Hematological disorders; Complications examined during the stay 3) Respiratory Support 2: Bilevel Positive Airway Pressure (BiPAP); Extracorporeal membrane oxygenation (ECMO); High flow; Nasal cannula; Non-rebreather; Oxygen conserving device; Simple mask; Mechanical Ventilation 4) Markers of illness severity: Intensive Care Unit (ICU) admission; Invasive mechanical ventilation<sup>2</sup>; Supplemental oxygen<sup>2</sup>; Death 1) Potential COVID-19 treatments: Remdesivir; Tocilizumab; Sarilumab; Eculizumab; Methylprednisolone; Lopinavir / Ritonavir; Norepinephrine; Dexamethasone; Baricitinib; Bamlanivimab; Casirivimab / Imdevimab; Bamlanivimab and Etesevimab Medications administered 2) Antibiotic use: Any antibiotic; Azithromycin; Doxycycline during the stay 3) Antithrombotic medications: Low molecular weight heparin; Tissue plasminogen activator; Vitamin K antagonists; Factor Xa inhibitors; Thrombin inhibitors; Anti-platelet therapy Examined Death at discharge

Cohort identification criteria: index date is admission date (Day 0), exit date is discharge date